RE:Market Exclusivity for 'novel' biological drug productsAnd YES ... ONCY's pelareorep is a "different kettle of fish" since this is not only a platform technology but is also an immune stimulant that is capable of activating both the innate and adaptive immune system while converting an immunosuppressive and hypoxic tumor microenvironment environment (TME) thus making the TME conducive for the addition of PD-(L)1 checkpoint inhibitors.
Furthermore the PD-L1 checkpoint inhibitor market is expected to be in excess of US$ 120 Billion by 2027.
ONCY 's pelareorep is intending to expanding the effectiveness of CPIs by 2-3x which will correspondingly expand the market size to a proportionate degree.